Calgary, Canada (ots/PRNewswire) - - Canadian Biotechnology Company Updates Progress and Upcoming Milestones on its Insulin Program - TSX symbol: SBS SemBioSys Genetics Inc. (TSX:SBS), a biotechnology company developing a portfolio of therapeutic proteins for metabolic and cardiovascular disease, today announced positive preclinical data supporting the ...
Chicago (ots/PRNewswire) - -- BYETTA offers added benefits of progressive weight loss in an analysis of the longest extension study to date -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced three-year, open-label study results that showed treatment with ...
Indianapolis (ots/PRNewswire) - - Daily dosing option is first prescription oral treatment to offer uninterrupted management of erectile dysfunction in select men Lilly (NYSE: LLY) announced today that the European Commission has granted marketing authorization for Cialis(R) (tadalafil)(1) 2.5 mg and 5 ...
Chicago (ots/PRNewswire) - -- When compared to insulin glargine, BYETTA offers the added benefits of progressive weight loss and lower risk of hypoglycaemia when used with metformin -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced study results comparing treatment with BYETTA(R)(exenatide) injection with insulin glargine in people with type 2 diabetes. Study ...
Basel, Switzerland (ots/PRNewswire) - An analysis of two large-scale Phase III maintenance studies on C.E.R.A. has highlighted that two high-risk patient populations - dialysis patients with diabetes and/or coronary artery disease - consistently and safely maintained their haemoglobin (Hb) levels at target levels ...
Chicago (ots/PRNewswire) - - Study also showed added benefits of reductions in cardiovascular risk factors and progressive weight loss - Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced results from a study that showed BYETTA(R) (exenatide) injection in ...
Basel, Switzerland (ots/PRNewswire) - - New Study Reveals Potential for Improved use of Resources Whilst Maintaining High Quality Anaemia Management A new study has found that converting dialysis patients from more frequently administered erythropoiesis-stimulating agents (ESAs) to once-monthly C.E.R.A., ...
Basel, Switzerland (ots/PRNewswire) - - First Ever Economic Analysis Shows Tamiflu Use in a Pandemic Could Save Significant Costs to Society Treatment with the oral antiviral Tamiflu (oseltamivir) and prophylaxis for people exposed to infected patients could be one of the most cost-effective strategies for reducing illness and death during an influenza ...
Indianapolis and Brussels, Belgium (ots/PRNewswire) - - Global contest seeks expressions of the triumphs and challenges of living with diabetes through art, essay, poetry, photography and music Eli Lilly and Company and the International Diabetes Federation (IDF) today announced the global launch of the ...
Alderley Park, England (ots/PRNewswire) - - FOR NON-US HEALTHCARE PROFESSIONAL PRESS ONLY - AstraZeneca Collaborates With Myriad Genetics on Phase 2 Trials AstraZeneca (NYSE: AZN) today announced the start of two Phase II trials for a new compound being tested to treat patients with BRCA 1 & 2 ...
Oss, The Netherlands (ots/PRNewswire) - Organon announced today that NuvaRing(R) (etonogestrel/ethinyl estradiol vaginal ring), the company's once-a-month contraceptive, has successfully completed the European Mutual Recognition Procedure (MRP) in an additional 13 countries (1). NuvaRing is already approved in 14 European Union territories using the Mutual ...
Irvine, California (ots/PRNewswire) - IsoTis, Inc. (NASDAQ: ISOT), the orthobiologics company, today announced that it is at the final stage of concluding the Exchange Offer it launched for all of the outstanding shares of ISOTIS SA on December 15, 2006. After this last step of the Exchange Offer, ISOTIS SA will no longer be listed on SWX Swiss Exchange, Euronext Amsterdam and the Toronto Stock Exchange. On ...
Milan, Italy (ots/PRNewswire) - - For non-US Healthcare Media Today AMADEO, one of the first studies to compare the protective potential of two angiotensin receptor blockers in hypertensive patients with diabetic nephropathy, was presented at the European Society of Hypertension, Milan. The results from ...
Milan, Italy (ots/PRNewswire) - - For non-US Healthcare Media - Results From Two Large, Multinational, Practice-Based Observational Studies in Blood Pressure New data announced today at the Annual European Society of Hypertension (ESH) show that measuring blood pressure in a doctor's office alone does ...
Astellas Pharma Europe Limited
London (ots/PRNewswire) - Astellas today announced that Advagraf(R) (generic name: tacrolimus, prolonged release), a once-daily immunosuppressant for use in organ transplantation, is now available in Germany and the UK. The European Commission approved Advagraf(R) on April 23, 2007 for the prophylaxis of ...
Beerse, Belgium (ots/PRNewswire) - Janssen-Cilag International NV has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMEA) for ceftobiprole, an investigational antibiotic for the treatment of complicated skin and soft tissue infections (cSSTI) including diabetic foot ...
Malvern, Pennsylvania (ots/PRNewswire) - Solstice Neurosciences, Inc. today reported important results from a multicenter, forced dose escalation study of Botulinum Toxin Type B Injectable Solution (Myobloc(R)) recently presented at the 11th International Congress of The Movement Disorders Society in ...
London (ots/PRNewswire) - - First Treatment Licensed Specifically for LGS Offers New Hope for Patients With Epilepsy Eisai Europe Limited, (Headquarters: London, President Yutaka Tsuchiya) today announced the launch in Germany and Scandinavia of its new anti-epileptic agent Inovelon (rufinamide) indicated for adjunctive therapy in Lennox-Gastaut Syndrome ...
Basel, Switzerland (ots/PRNewswire) - - New Data Supports IL-6 Receptor Inhibition as a Key Component in Controlling Inflammation From RA Roche today announced significant results from 'OPTION'(1), the first rheumatoid arthritis multinational phase III study of Actemra (tocilizumab) outside of Japan. The ...
Basel, Switzerland (ots/PRNewswire) - Eight presentations regarding Roche's new anti-anaemia drug MIRCERA(R) currently awaiting approval worldwide, will feature strongly at the upcoming European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress in Barcelona Spain, June 21st to 24th 2007. Three MIRCERA abstracts have received the ...
Copenhagen, Denmark (ots/PRNewswire) - - Summary: Genmab has Initiated a Phase II Study of Ofatumumab in Combination With CHOP as Front Line Treatment of Follicular NHL. Genmab A/S (CSE: GEN) announced today it has initiated a Phase II study of ofatumumab (HuMax-CD20(R)) in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) in patients with previously untreated follicular ...
Global Lung Cancer Coalition (GLCC)
London (ots/PRNewswire) - The Lung Cancer Journalism Awards' mission: to raise global awareness of the leading cause of cancer-related deaths worldwide. Winners receive: - Global showcase recognising their prize-winning work - EUR7,000 research grant Enter to win 3 different ...
Ingelheim, Germany (ots/PRNewswire) - Boehringer Ingelheim GmbH announced today that it has begun to enroll patients in the SPRING study. The SPRING study will be one of the largest racially and gender diverse international studies of highly treatment-experienced HIV-1 infected patients. The trial ...
Oss, The Netherlands (ots/PRNewswire) - Sugammadex - the novel selective relaxant binding agent (SRBA) being developed by Organon, the human healthcare business unit of Akzo Nobel - demonstrated in a Phase III pivotal trial a 9-12 times faster reversal of neuromuscular blockade as compared to neostigmine, without ...
Ingelheim Am Rhein, Germany (ots/PRNewswire) - - Studies Reinforce the Benefits of Pramipexole From Daytime Symptom Control, Including Afternoon and Early Evening Onset - For Healthcare Media Outside the U.S.A. New data demonstrate that pramipexole (Mirapexin(R)/Sifrol(R)) is also efficacious and ...
Edmonton, Canada (ots/PRNewswire) - - Trades on Toronto Stock Exchange - (TSX:ISA) - www.isotechnika.com Isotechnika today announced that the Company has received a No Objection Letter from Health Canada for the long term use of ISA247 in patients currently participating in the Canadian arm of the Company's Phase 2b kidney transplant trial. The No ...
Brussels (ots/PRNewswire) - Led by British MEP Liz Lynne, medical experts and representatives of relevant patient and professional associations today called on the European Commission and the Council to recognise asthma as a serious public health issue. The statement is part of the Brussels Declaration, a 10-point action plan for improving asthma management across ...
Basel, Switzerland (ots/PRNewswire) - - First Publication of Phase III Data in the Clinical Journal of the American Society of Nephrology Results from a multi-centre renal anaemia study show that switching patients directly from frequent doses of epoetin therapies (epoetin alfa or beta administered one to ...
Edmonton, Canada (ots/PRNewswire) - - Trades on Toronto Stock Exchange - (TSX:ISA) Isotechnika Inc. announced today that the Company received approval from the Polish Competent Authority for participation in the ongoing Phase 3 European/Canadian clinical trial. This trial investigates the use of ISA247 ...
Chicago (ots/PRNewswire) - - Oral Xeloda(R) Combination Effective and Time-Saving Data presented today at the American Society of Clinical Oncology Annual Meeting (ASCO) in Chicago showed that not only is XELOX as effective as intravenous (i.v.) drug regimens, but that colorectal cancer patients who ...